Trials / Completed
CompletedNCT00199043
Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma
Randomised Phase III Trial of Effectivity and Safety of Rasburicase Compared With Allopurinol for Treatment of Hyperuricemia in Patients With Acute Lymphoblastic Leukemia or High-Grade NHL With High Risk of Tumorlysis Syndrome (> 15 Yrs)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Goethe University · Academic / Other
- Sex
- All
- Age
- 15 Years
- Healthy volunteers
- Not accepted
Summary
In this study the efficacy and tolerability of two approaches to treat and prevent hyperuricemia is tested in patients with acute lymphoblastic leukemia or high-grade lymphoma with high risk of tumor lysis syndrome. Both arms are compared by randomisation. In one arm patients receive during pre-phase chemotherapy conventional prophylaxis with allopurinol whereas in the other arm Rasburicase is used.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Allopurinol | |
| DRUG | Rasburicase |
Timeline
- Start date
- 2003-05-01
- Primary completion
- 2008-05-01
- Completion
- 2008-05-01
- First posted
- 2005-09-20
- Last updated
- 2023-03-17
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00199043. Inclusion in this directory is not an endorsement.